Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doripenem vs Imipenem in VAP or cIAI
NCT00515034Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of doripenem in ventilator-associated pneumonia (VAP) and Intra-abdominal infection (IAI) (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Treatment-Emergent Adverse Events. Started Oct 2007; status: completed.
02
Drugs
doripenem
03
Conditions
ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT00515034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515034.